These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25218668)

  • 1. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.
    Chak A; Buttar NS; Foster NR; Seisler DK; Marcon NE; Schoen R; Cruz-Correa MR; Falk GW; Sharma P; Hur C; Katzka DA; Rodriguez LM; Richmond E; Sharma AN; Smyrk TC; Mandrekar SJ; Limburg PJ;
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):665-72.e1-4. PubMed ID: 25218668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Controlled Trial of the Gastrin/CCK
    Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
    Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
    Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
    J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.
    Duggan C; Onstad L; Hardikar S; Blount PL; Reid BJ; Vaughan TL
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):934-43. PubMed ID: 23466711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
    Falk GW; Buttar NS; Foster NR; Ziegler KL; Demars CJ; Romero Y; Marcon NE; Schnell T; Corley DA; Sharma P; Cruz-Correa MR; Hur C; Fleischer DE; Chak A; Devault KR; Weinberg DS; Della'Zanna G; Richmond E; Smyrk TC; Mandrekar SJ; Limburg PJ;
    Gastroenterology; 2012 Oct; 143(4):917-26.e1. PubMed ID: 22796132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
    Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
    Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.
    Peng S; Huo X; Rezaei D; Zhang Q; Zhang X; Yu C; Asanuma K; Cheng E; Pham TH; Wang DH; Chen M; Souza RF; Spechler SJ
    Am J Physiol Gastrointest Liver Physiol; 2014 Jul; 307(2):G129-39. PubMed ID: 24852569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretory Phospholipase A
    Gergen AK; Jarrett MJ; Li A; White AM; Meng X; Fullerton DA; Weyant MJ
    J Surg Res; 2021 Mar; 259():562-568. PubMed ID: 33261858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of Chemoprevention in Barrett's Esophagus.
    Moayyedi P; El-Serag HB
    Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin use and the risk of esophageal cancer in Barrett esophagus.
    Agrawal S; Patel P; Agrawal A; Makhijani N; Markert R; Deidrich W
    South Med J; 2014 Dec; 107(12):774-9. PubMed ID: 25502158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of metformin on apoptosis in a breast cancer presurgical trial.
    Cazzaniga M; DeCensi A; Pruneri G; Puntoni M; Bottiglieri L; Varricchio C; Guerrieri-Gonzaga A; Gentilini OD; Pagani G; Dell'Orto P; Lazzeroni M; Serrano D; Viale G; Bonanni B
    Br J Cancer; 2013 Nov; 109(11):2792-7. PubMed ID: 24157825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc Gluconate Induces Potentially Cancer Chemopreventive Activity in Barrett's Esophagus: A Phase 1 Pilot Study.
    Valenzano MC; Rybakovsky E; Chen V; Leroy K; Lander J; Richardson E; Yalamanchili S; McShane S; Mathew A; Mayilvaganan B; Connor L; Urbas R; Huntington W; Corcoran A; Trembeth S; McDonnell E; Wong P; Newman G; Mercogliano G; Zitin M; Etemad B; Thornton J; Daum G; Raines J; Kossenkov A; Fong LY; Mullin JM
    Dig Dis Sci; 2021 Apr; 66(4):1195-1211. PubMed ID: 32415564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
    Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
    Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
    Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
    Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.
    Sarr MG; Hamilton SR; Marrone GC; Cameron JL
    Am J Surg; 1985 Jan; 149(1):187-93. PubMed ID: 3966636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.
    Dong LM; Kristal AR; Peters U; Schenk JM; Sanchez CA; Rabinovitch PS; Blount PL; Odze RD; Ayub K; Reid BJ; Vaughan TL
    Nutr Cancer; 2008; 60(1):39-48. PubMed ID: 18444134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.